Neurodegenerative diseases are a broad heterogeneous group affecting the nervous system. They are characterized, from a pathophysiological perspective, by the selective involvement of a subpopulation of nerve cells with a consequent clinical picture of a disease. Clinical diagnoses of neurodegenerative diseases are quite challenging and often not completely accurate because of their marked heterogeneity and frequently overlapping clinical pictures. Efforts are being made to define sufficiently specific and sensitive markers for individual neurodegenerative diseases or groups of diseases in order to increase the accuracy and speed of clinical diagnosis. Thus said, this present research aimed to identify biomarkers in the cerebrospinal fluid (CSF) and serum (α-synuclein [α-syn], tau protein [t-tau], phosphorylated tau protein [p-tau], β-amyloid [Aβ], clusterin, chromogranin A [chromogrA], cystatin C [cyst C], neurofilament heavy chains [NFH], phosphorylated form of neurofilament heavy chains [pNF-H], and ratio of tau protein/amyloid beta [Ind tau/Aβ]) that could help in the differential diagnosis and differentiation of the defined groups of α-synucleinopathies and four-repeat (4R-) tauopathies characterized by tau protein isoforms with four microtubule-binding domains. In this study, we analyzed a cohort of 229 patients divided into four groups: (1) Parkinson's disease (PD) + dementia with Lewy bodies (DLB) (n = 82), (2) multiple system atrophy (MSA) (n = 25), (3) progressive supranuclear palsy (PSP) + corticobasal syndrome (CBS) (n = 30), and (4) healthy controls (HC) (n = 92). We also focused on analyzing the biomarkers in relation to each other with the intention of determining whether they are useful in distinguishing among individual proteinopathies. Our results indicate that the proposed set of biomarkers, when evaluated in CSF, is likely to be useful for the differential diagnosis of MSA versus 4RT. However, these biomarkers do not seem to provide any useful diagnostic information when assessed in blood serum.

Department of Chemical Biology Faculty of Science Palacky University Olomouc Czech Republic

Department of Neurology and Psychiatry Neuroscience Institute University of Santo Tomas Hospital Manila Philippines

Department of Neurology Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Department of Neurology Santa Maria University Hospital Terni Italy

Department of Neurology University Hospital Olomouc Olomouc Czech Republic

Department of Pathology and Molecular Medicine 3rd Faculty of Medicine Charles University Thomayer University Hospital Prague Czech Republic

Laboratory of Growth Regulators Institute of Experimental Botany of the Czech Academy of Sciences Palacky University Olomouc Czech Republic

Laboratory of Inherited Metabolic Disorders Faculty of Medicine and Dentistry Palacky University University Hospital Olomouc Olomouc Czech Republic

Neurology Outpatient Clinic St Moritz Olomouc Czech Republic

Zobrazit více v PubMed

Aguirre, J. D., Dunkerley, K. M., Lam, R., Rusal, M., & Shaw, G. S. (2018). Impact of altered phosphorylation on loss of function of juvenile parkinsonism-associated genetic variants of the E3 ligase parkin. Journal of Biological Chemistry, 293(17), 6337-6348. https://doi.org/10.1074/jbc.RA117.000605

Alexander, S. K., Rittmen, T., Xuereb, J. H., Bak, T. H., Hodges, J. R., & Rowe, J. B. (2014). Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 85(8), 925-929. https://doi.org/10.1136/jnnp-2013-307035

Andersen, A. D., Binzer, M., Stenager, E., & Gramsbergen, J. B. (2017). Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review. Acta Neurologica Scandinavica, 135(1), 34-56. https://doi.org/10.1111/ane.12590

Angelopoulou, E., Paudel, Y. N., Shaikh, M. F., & Piperi, C. (2020). Fractalkine (CX3CL1) signaling and neuroinflammation in Parkinson's disease: Potential clinical and therapeutic implications. Pharmacological Research, 158, 104930. https://doi.org/10.1016/j.phrs.2020.104930

Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., Josephs, K. A., Kertesz, A., Lee, S. E., Miller, B. L., Raich, S. G., Rilez, D. E., Tolosa, E., Tröster, A. I., Vidaihlet, M., & Weiner, W. J. (2013). Criteria for the diagnosis of corticobasal degeneration. Neurology, 80(5), 496-503. https://doi.org/10.1212/WNL.0b013e31827f0fd1

Atik, A., Stewart, T., & Zhang, J. (2016). Alpha-synuclein as a biomarker for Parkinson's disease. Brain Pathology, 26(3), 410-418. https://doi.org/10.1111/bpa.12370

Barba, L., Paoletti, F. P., Bellomo, G., Gaetani, L., Halbgebauer, S., Oeckl, P., Otto, M., & Parnetti, L. (2022). Alpha and beta synucleins: From pathophysiology to clinical application as biomarkers. Movement Disorders, 37(4), 669-683. https://doi.org/10.1002/mds.28941

Batla, A., Stamelou, M., Mensikova, K., Kaiserova, M., Tuckova, L., Kanovsky, P., Quinn, N., & Bhatia, K. P. (2013). Markedly asymmetric presentation in multiple system atrophy. Parkinsonism & Related Disorders, 19(10), 901-905. https://doi.org/10.1016/j.parkreldis.2013.05.004

Bhidayasiri, R., Rattanachaisit, W., Phokaewvarangkul, O., Lim, T. T., & Fernandez, H. H. (2019). Exploring bedside clinical features of parkinsonism: A focus on differential diagnosis. Parkinsonism & Related Disorders, 59, 74-81. https://doi.org/10.1016/j.parkreldis.2018.11.005

Boxer, A. L., Yu, J. T., Golbe, L. I., Litvan, I., Lang, A. E., & Höglinger, G. U. (2017). Advances in progressive supranuclear palsy: New diagnostic criteria, biomarkers, and therapeutic approaches. The Lancet Neurology, 16(7), 552-563. https://doi.org/10.1016/S1474-4422(17)30157-6

Cong, S., Xiang, C., Wang, H., & Cong, S. (2021). Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis. Journal of Neurology, 268(8), 2703-2712. https://doi.org/10.1007/s00415-020-09781-9

Emamzadeh, F. N., & Surguchov, A. (2018). Parkinson's disease: Biomarkers, treatment, and risk factors. Frontiers in Neuroscience, 12, 612. https://doi.org/10.3389/fnins.2018.00612

Farníková, K., Kaňovský, P., Nestrašil, I., & Otruba, P. (2010). Coexistence of parkinsonism, dementia and upper motor neuron syndrome in four Czech patients. Journal of Neurological Sciences, 296(1-2), 47-54. https://doi.org/10.1016/j.jns.2010.06.011

Gaetani, L., Paoletti, F. P., Bellomo, G., Mancini, A., Simoni, S., Di Filippo, M., & Parnetti, L. (2020). CSF and blood biomarkers in neuroinflammatory and neurodegenerative diseases: Implications for treatment. Trends in Pharmacological Sciences, 41(12), 1023-1037. https://doi.org/10.1016/j.tips.2020.09.011

Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., Kaufmann, H., Klockgether, T., Lees, A., Poewe, W., Quinn, N., Revesz, T., Robertson, D., Sandroni, P., Seppi, K., & Vidaihet, M. (2008). Second consensus statement on the diagnosis of multiple system atrophy. Neurology, 71(9), 670-676. https://doi.org/10.1212/01.wnl.0000324625.00404.15

Höglinger, G. U., Responek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., Arzberger, T., Englund, E., Gelpi, E., Giese, A., Irwin, D. J., Meissner, W. G., Pantelyat, A., Rajput, A., van Swieten, J. C., … Movement Disorder Society-Endorsed PSP Study Group. (2017). Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 32(6), 853-864. https://doi.org/10.1002/mds.26987

Jabbari, E., Woodside, J., Guo, T., Magdalinou, N. K., Chelban, V., Athauda, D., Lees, A. J., Foltynie, T., Houlden, H., Church, A., Hu, M. T., Rowe, J. B., Zetterberg, H., & Morris, H. R. (2019). Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 90(7), 768-773. https://doi.org/10.1136/jnnp-2018-320151

Kaiserova, M., Chudackova, M., Mensikova, K., Vastik, M., Kurcova, S., Prikrylova Vranova, H., Stejskal, D., & Kanovsky, P. (2021). Cerebrospinal fluid levels of chromogranin a in Parkinson's disease and multiple system atrophy. Brain Sciences, 11(2), 141. https://doi.org/10.3390/brainsci11020141

Koníčková, D., Menšíková, K., Tučková, L., Hényková, E., Strnad, M., Friedecký, D., Stejskal, D., Matěj, R., & Kaňovský, P. (2022). Biomarkers of neurodegenerative diseases: Biology, taxonomy, clinical relevance, and current research status. Biomedicine, 10(7), 1760. https://doi.org/10.3390/biomedicines10071760

Kovacs, G. G. (2016). Molecular pathological classification of neurodegenerative diseases: Turning towards precision medicine. International Journal of Molecular Sciences, 17(2), 189. https://doi.org/10.3390/ijms17020189

Kovacs, G. G. (2019). Molecular pathology of neurodegenerative diseases: Principles and practice. Journal of Clinical Pathology, 72(11), 725-735. https://doi.org/10.1136/jclinpath-2019-205952

Kovacs, G. G., Ghetti, B., & Goedert, M. (2022). Classification of diseases with accumulation of tau protein. Neuropathology and Applied Neurobiology, 48(3), e12792. https://doi.org/10.1111/nan.12792

Li, Q., Li, Z., Han, X., Shen, X., Wang, F., Bai, L., Li, Z., Zhang, R., Wang, Y., & Zhu, X. (2022). A panel of plasma biomarkers for differential diagnosis of parkinsonian syndromes. Frontiers in Neuroscience, 16, 805953. https://doi.org/10.3389/fnins.2022.805953

Magdalinou, N. K., Noyce, A. J., Pinto, R., Lindstrom, E., Holmén-Larsson, J., Holtta, M., Blennow, K., Morris, H. R., Skillbäk, T., Warner, T. T., Lees, A. J., Pike, I., Ward, M., Zetterberg, H., & Gobom, J. (2017). Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Parkinsonism & Related Disorders, 37, 65-71. https://doi.org/10.1016/j.parkreldis.2017.01.016

Magdalinou, N. K., Paterson, R. W., Schott, J. M., Fox, N. C., Mummery, C., Blennow, K., Bhatia, K., Morris, H. R., Giunti, P., Warner, T. T., de Silva, R., Lees, A. J., & Zetterberg, H. (2015). A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 86(11), 1240-1247. https://doi.org/10.1136/jnnp-2014-309562

Marques, T. M., van Rumund, A., Kersten, I., Bruinsma, I. B., Wessels, H. J. C. T., Gloerich, J., Kaffa, C., Esselink, R. A. J., Bloem, B. R., Kuiperij, H. B., & Verbeek, M. M. (2021). Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach. npj Parkinson's Disease, 7(1), 107. https://doi.org/10.1038/s41531-021-00249-9

Mavroudis, I., Petridis, F., & Kazis, D. (2019). Cerebrospinal fluid, imaging, and physiological biomarkers in dementia with Lewy bodies. American Journal of Alzheimer's Disease and Other Dementias, 34(7-8), 421-432. https://doi.org/10.1177/1533317519869700

McKeith, I. G., Ferman, T. J., Thomas, A. J., Blanc, F., Boeve, B. F., Fujishiro, H., Kantarci, K., Muscio, C., O'Brien, J. T., Postuma, R. B., Aarsland, D., Ballard, C., Bonanni, L., Donaghy, P., Emre, M., Galvin, J. E., Galasko, D., Goldman, J. G., Gomperts, S. N., … Prodromal DLB Diagnostic Study Group. (2020). Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology, 94(17), 743-755. https://doi.org/10.1212/WNL.0000000000009323

Menšíková, K., Tučková, L., Kolaříková, K., Bartoníková, T., Vodička, R., Ehrmann, J., Vrtěl, R., Procházka, M., Kaňovský, P., & Kovacs, G. G. (2019). Atypical parkinsonism of progressive supranuclear palsy-parkinsonism (PSP-P) phenotype with rare variants in FBXO7 and VPS35 genes associated with Lewy body pathology. Acta Neuropathologica, 137(1), 171-173. https://doi.org/10.1007/s00401-018-1923-y

Parnetti, L., Paciotti, S., Farotti, L., Bellomo, G., Sepe, F. N., & Eusebi, P. (2019). Parkinson's and Lewy body dementia CSF biomarkers. Clinica Chimica Acta, 495, 318-325. https://doi.org/10.1016/j.cca.2019.04.078

Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., Hallidaz, G., Goetz, C. G., Gasser, T., Dubois, B., Chan, P., Bloem, B. R., Adler, C. H., & Deuschl, G. (2015). MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 30(12), 1591-1601. https://doi.org/10.1002/mds.26424

Přikrylová Vranová, H., Mareš, J., Nevrlý, M., Stejskal, D., Zapletalová, J., Hluštík, P., & Kaňovský, P. (2010). CSF markers of neurodegeneration in Parkinson's disease. Journal of Neural Transmission, 117(10), 1177-1181. https://doi.org/10.1007/s00702-010-0462-z

Schulz, I., Kruse, N., Gera, R. G., Kremer, T., Cedarbaum, J., Barbour, R., Zago, W., Schade, S., Otte, B., Bartl, M., Hutten, S. J., Trenkwalder, C., & Mollenhauer, B. (2021). Systematic assessment of 10 biomarker candidates focusing on α-synuclein-related disorders. Movement Disorders, 36(12), 2874-2887. https://doi.org/10.1002/mds.28738

Swift, I. J., Sogorb-Esteve, A., Heller, C., Synozik, M., Otto, M., Graff, C., Galimberti, D., Todd, E., Heslegrave, A. J., van der Ende, E. L., Van Swieten, J. C., Zetterberg, H., & Rohrer, J. D. (2021). Fluid biomarkers in frontotemporal dementia: Past, present and future. Journal of Neurology, Neurosurgery and Psychiatry, 92(2), 204-215. https://doi.org/10.1136/jnnp-2020-323520

Tarutani, A., Adachi, T., Akatsu, H., Hashizume, A., Hasegawa, K., Saito, Y., Robinson, A. C., Mann, D. M. A., Yoshida, M., Murayama, S., & Hasegawa, M. (2022). Ultrastructural and biochemical classification of pathogenic tau, α-synuclein and TDP-43. Acta Neuropathologica, 143(6), 613-640. https://doi.org/10.1007/s00401-022-02426-3

Xiang, C., Cong, S., Tan, X., Ma, S., Liu, Y., Wang, H., & Cong, S. (2022). A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson's disease. npj Parkinson's Disease, 8(1), 165. https://doi.org/10.1038/s41531-022-00431-7

Xie, D., Feng, L., Huang, H., Zhao, Q., Ning, P., Shen, Q., Lu, H., Xu, F., & Xu, Y. (2021). Cerebrospinal fluid biomarkers in multiple system atrophy relative to Parkinson's disease: A meta-analysis. Behavioural Neurology, 2021, 5559383. https://doi.org/10.1155/2021/5559383

Simultaneous Determination of Selected Steroids with Neuroactive Effects in Human Serum by Ultrahigh-Performance Liquid Chromatography-Tandem Mass Spectrometry

Patients with Neurodegenerative Proteinopathies Exhibit Altered Tryptophan Metabolism in the Serum and Cerebrospinal Fluid